USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions
USPSTF recommends against hormone therapy for primary prevention of chronic conditions in postmenopausal persons
Menopause and HRT
Suvorexant May Aid Insomnia Tied to Hot Flashes
Nighttime hot flashes, insomnia severity both down at four weeks versus placebo
Oral Contraceptive Use Tied to Marker of Ovarian Function
Longer duration of oral contraceptive use, certain types of tubal ligation associated with lower levels of antimüllerian hormone
Long-Term Bone Loss Studied in Postmenopausal Women
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
Hormone Therapy Not Tied to T2DM, CV Risk in Postmenopausal Women
No associations observed in large study of middle-aged, postmenopausal Korean women
Risk for Dementia Not Increased With Menopausal Hormone Therapy
Risk for dementia decreased for cases and controls younger than 80 years who had been taking estrogen-only therapy for 10 years or more
Women Report Using Cannabis to Relieve Menopause Symptoms
Survey reveals that some women believe cannabis helps with symptoms that overlap with menopause, such as sleep issues and anxiety
NAMS Updates Position Statement on Osteoporosis Management
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Hormone Therapy May Reduce Nocturia After Menopause
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause
Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.
